ABT - Company ID 0000001800
The table below shows ABBOTT LABORATORIES's balance sheet line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $8.52B | $7.62B | $6.90B | $9.88B | $9.80B | $6.84B |
| Short-term investments | $417.00M | $351.00M | $383.00M | $288.00M | $450.00M | $310.00M |
| Receivables | $7.93B | $6.92B | $6.57B | $6.22B | $6.49B | $6.41B |
| Inventory | $6.49B | $6.19B | $6.57B | $6.17B | $5.16B | $5.01B |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Total current assets |
| $26.00B |
| $23.66B |
| $22.67B |
| $25.22B |
| $24.24B |
| $20.44B |
| Property, plant & equipment | $11.82B | $10.66B | $10.15B | $9.16B | $8.96B | $9.03B |
| Goodwill | $24.04B | $23.11B | $23.68B | $22.80B | $23.23B | $23.74B |
| Total assets | $86.71B | $81.41B | $73.21B | $74.44B | $75.20B | $72.55B |
| Accounts payable | - | - | - | - | - | - |
| Total current liabilities | $16.50B | $14.16B | $13.84B | $15.49B | $13.11B | $11.91B |
| Long-term debt | $9.90B | $12.63B | $13.60B | $14.52B | $17.30B | $18.53B |
| Total liabilities | - | - | - | - | - | - |
| Retained earnings | $49.78B | $47.26B | $37.55B | $35.26B | $31.53B | $27.63B |
| Total equity | $52.13B | $47.66B | $38.60B | $36.69B | $35.80B | $32.78B |